Farcas_Alex_46694

Alex Farcas

Partner
Baker & McKenzie LLP

Biography

Alex Farcas is a member of the North America Corporate & Securities Group. Alex focuses his practice on a variety of transactional matters with particular emphasis on public and private capital market transactions and domestic and cross-border M&A. He also advises on corporate governance, capital market regulatory compliance and other securities-related matters.

Practice Focus

Alex has extensive experience acting for underwriters and issuers in private placements and public offerings and regularly advises issuers in connection with going public transactions and listing applications on the Toronto Stock Exchange, the TSX Venture Exchange and the Canadian Securities Exchange. Alex is also frequently involved in advising on complex public and private M&A transactions. He has acted for clients in a wide range of industries including technology, life sciences, biotech, pharma, mining, oil and gas, renewable energy and financial services.

Representative Legal Matters

  • Represented Catamaran Corporation on its USD12.8 billion merger with OptumRx, UnitedHealth Groups' free-standing pharmacy care services business.
  • Represented VASCO Data Security International Inc. on the USD85 million acquisition of Canada-based Silanis Technology Inc.
  • Represented the special committee of YM BioSciences Inc. in connection with the CAD510 million sale of YM to Gilead Sciences Inc.
  • Represented Iberian Minerals Corp. in respect of its CAD298.7 million takeover bid offer by Trafigura Beheer B.V.
  • Represented Evergreen Industries Group in its CAD115 million takeover bid of MagIndustries Corp.
  • Represented a Japanese consortium in connection with its CAD186 million joint venture investment in a Canadian mining project.
  • Represented the purchaser in separate acquisitions of a mining cadastre software company and a crane equipment manufacturer.
  • Acted for a syndicate of agents on a brokered equity private placement and syndicated loan to finance in part the acquisition by HLS Therapeutics Inc. of the US and Canadian rights to Clozaril® (clozapine) from Novartis AG.
  • Acted for the agents in connection with two public offerings of units of Titan Medical Inc. for aggregate gross proceeds of CAD25 million.
  • Acted for a syndicate of underwriters in connection with CAD40 million public offering of common shares of Sulliden Gold Corporation.

Professional Associations and Memberships

  • Law Society of Ontario - Member
  • Ontario Bar Association - Member
  • Canadian Bar Association - Member
  • Prospectors and Developers Association of Canada - Member

Admissions

  • Ontario~Canada (2009)

Education

  • York University (Osgoode Hall) (LL.B.) (2008)

Languages

  • English
  • Romanian